management of myelofibrosis: jak inhibitors and novel therapeutics in the peri-transplant setting
Published 2 years ago • 303 plays • Length 1:03:11Download video MP4
Download video MP3
Similar videos
-
37:14
risk-adapted treatment in myelofibrosis: jak inhibitors and novel combination therapies
-
58:48
how to manage jak inhibition in patients undergoing hct
-
1:20:00
understanding myelofibrosis: molecular biology, jak inhibitors, and emerging therapeutics
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
1:34:09
jak inhibitors in myelofibrosis: expert insights on cases in personalizing therapy
-
16:10
stem cell transplant for myelofibrosis in the jak2 inhibitor era
-
4:22
what do patients with myelofibrosis need to know?
-
17:41
for myelofibrosis patients: the latest on promising treatments from top specialist | dr. ruben mesa
-
13:48
understanding treatment options for et, pv, and myelofibrosis
-
21:52
stem cell transplant for myelofibrosis in the jak2 inhibitor era
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
25:13
update on jak inhibitors for myelofibrosis: there is more than one
-
3:52
optimizing the selection between available jak inhibitors in myelofibrosis
-
25:15
how to manage side effects of jak inhibitors for mylofibrosis in the clinical practice
-
19:04
my view on current and future use of jak inhibitors for et, pv, and mf
-
14:28
survival benefit of jak inhibition in mf: jak inhibitor for all mf patients?
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
2:20
jak inhibition in mf: monotherapy versus combination treatment
-
0:46
xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis
-
19:11
novel agents and combination therapies in myelofibrosis
-
3:48
jak inhibition for the early treatment of myelofibrosis